AAPL356.27+1.39 (+0.39%) ▲|ABBV295.03+0.58 (+0.20%) ▲|ABT108.52+1.27 (+1.18%) ▲|ACN250.49+0.54 (+0.22%) ▲|ADBE243.08+4.54 (+1.90%) ▲|AMAT370.50-10.45 (-2.74%) ▼|AMD534.06-51.24 (-8.75%) ▼|AMGN465.67-1.39 (-0.30%) ▼|AMT191.64+1.85 (+0.97%) ▲|AMZN266.66-0.78 (-0.29%) ▼|AVGO347.01-17.35 (-4.76%) ▼|AXP320.60+2.54 (+0.80%) ▲|BA171.50-0.05 (-0.03%) ▼|BAC51.02+0.51 (+1.01%) ▲|BKNG159.58-1.62 (-1.01%) ▼|BLK1,222.91+6.30 (+0.52%) ▲|BMY63.43+1.11 (+1.78%) ▲|BNY153.41+0.62 (+0.41%) ▲|BRK-B592.94+3.11 (+0.53%) ▲|C124.01-0.05 (-0.04%) ▼|CAT600.20-5.08 (-0.84%) ▼|CL99.67+1.77 (+1.81%) ▲|CMCSA25.16+0.36 (+1.45%) ▲|COF195.08+1.48 (+0.76%) ▲|COP142.28+2.22 (+1.59%) ▲|COST1,106.21+14.00 (+1.28%) ▲|CRM217.84+0.27 (+0.12%) ▲|CSCO95.64-6.37 (-6.24%) ▼|CVS89.35-0.44 (-0.49%) ▼|CVX219.89+3.54 (+1.64%) ▲|DE673.54-5.25 (-0.77%) ▼|DHR233.02+0.86 (+0.37%) ▲|DIS118.97+0.74 (+0.63%) ▲|DUK129.16+1.66 (+1.30%) ▲|EMR166.38+0.06 (+0.03%) ▲|FDX324.14+4.84 (+1.52%) ▲|GD363.46+0.39 (+0.11%) ▲|GE331.81+0.95 (+0.29%) ▲|GEV803.13-15.36 (-1.88%) ▼|GILD168.08+0.13 (+0.08%) ▲|GM86.00-0.25 (-0.29%) ▼|GOOG292.52-2.83 (-0.96%) ▼|GOOGL295.77-2.93 (-0.98%) ▼|GS916.56+2.96 (+0.32%) ▲|HD348.69+0.43 (+0.12%) ▲|HON222.46-0.29 (-0.13%) ▼|IBM247.13+2.46 (+1.01%) ▲|INTC59.66-1.54 (-2.52%) ▼|INTU341.70+1.53 (+0.45%) ▲|ISRG443.59+3.70 (+0.84%) ▲|JNJ285.75+2.23 (+0.79%) ▲|JPM346.19+3.37 (+0.98%) ▲|KO99.25+1.81 (+1.86%) ▲|LIN526.06+3.57 (+0.68%) ▲|LLY1,443.50+17.95 (+1.26%) ▲|LMT596.04-8.05 (-1.33%) ▼|LOW227.73+0.27 (+0.12%) ▲|LRCX225.92-7.86 (-3.36%) ▼|MA661.19+8.59 (+1.32%) ▲|MCD271.97-1.66 (-0.61%) ▼|MDLZ67.54+0.98 (+1.47%) ▲|MDT102.86+1.87 (+1.85%) ▲|META641.69+18.08 (+2.90%) ▲|MMM183.66-1.80 (-0.97%) ▼|MO78.64+0.72 (+0.92%) ▲|MRK147.76+0.81 (+0.55%) ▲|MS190.65+1.48 (+0.78%) ▲|MSFT523.88+0.88 (+0.17%) ▲|MU778.31-20.13 (-2.52%) ▼|NEE85.12-0.17 (-0.20%) ▼|NFLX62.15-0.54 (-0.86%) ▼|NKE37.99+0.23 (+0.61%) ▲|NOW102.25+1.59 (+1.58%) ▲|NVDA162.85-3.34 (-2.01%) ▼|ORCL125.35-1.76 (-1.38%) ▼|PEP145.44+3.18 (+2.24%) ▲|PFE28.89+0.06 (+0.21%) ▲|PG169.80+1.77 (+1.05%) ▲|PLTR167.99-3.59 (-2.09%) ▼|PM198.96+2.30 (+1.17%) ▲|QCOM172.47-4.67 (-2.64%) ▼|RTX198.58+0.22 (+0.11%) ▲|SBUX106.44-0.19 (-0.18%) ▼|SCHW92.98+1.58 (+1.73%) ▲|SO93.59+1.12 (+1.21%) ▲|SPG232.97-0.64 (-0.27%) ▼|T22.18+0.00 (+0.00%) ▲|TMO700.22+0.78 (+0.11%) ▲|TMUS169.95-1.08 (-0.63%) ▼|TSLA390.22-7.23 (-1.82%) ▼|TXN303.60-8.88 (-2.84%) ▼|UBER69.69+0.57 (+0.82%) ▲|UNH407.46+2.33 (+0.58%) ▲|UNP302.44-1.76 (-0.58%) ▼|UPS112.40+2.02 (+1.83%) ▲|USB60.99+0.52 (+0.86%) ▲|V425.76+5.45 (+1.30%) ▲|VZ46.36-0.19 (-0.41%) ▼|WFC86.05+0.29 (+0.34%) ▲|WMT128.09+1.90 (+1.51%) ▲|XOM170.59+0.81 (+0.48%) ▲|AAPL356.27+1.39 (+0.39%) ▲|ABBV295.03+0.58 (+0.20%) ▲|ABT108.52+1.27 (+1.18%) ▲|ACN250.49+0.54 (+0.22%) ▲|ADBE243.08+4.54 (+1.90%) ▲|AMAT370.50-10.45 (-2.74%) ▼|AMD534.06-51.24 (-8.75%) ▼|AMGN465.67-1.39 (-0.30%) ▼|AMT191.64+1.85 (+0.97%) ▲|AMZN266.66-0.78 (-0.29%) ▼|AVGO347.01-17.35 (-4.76%) ▼|AXP320.60+2.54 (+0.80%) ▲|BA171.50-0.05 (-0.03%) ▼|BAC51.02+0.51 (+1.01%) ▲|BKNG159.58-1.62 (-1.01%) ▼|BLK1,222.91+6.30 (+0.52%) ▲|BMY63.43+1.11 (+1.78%) ▲|BNY153.41+0.62 (+0.41%) ▲|BRK-B592.94+3.11 (+0.53%) ▲|C124.01-0.05 (-0.04%) ▼|CAT600.20-5.08 (-0.84%) ▼|CL99.67+1.77 (+1.81%) ▲|CMCSA25.16+0.36 (+1.45%) ▲|COF195.08+1.48 (+0.76%) ▲|COP142.28+2.22 (+1.59%) ▲|COST1,106.21+14.00 (+1.28%) ▲|CRM217.84+0.27 (+0.12%) ▲|CSCO95.64-6.37 (-6.24%) ▼|CVS89.35-0.44 (-0.49%) ▼|CVX219.89+3.54 (+1.64%) ▲|DE673.54-5.25 (-0.77%) ▼|DHR233.02+0.86 (+0.37%) ▲|DIS118.97+0.74 (+0.63%) ▲|DUK129.16+1.66 (+1.30%) ▲|EMR166.38+0.06 (+0.03%) ▲|FDX324.14+4.84 (+1.52%) ▲|GD363.46+0.39 (+0.11%) ▲|GE331.81+0.95 (+0.29%) ▲|GEV803.13-15.36 (-1.88%) ▼|GILD168.08+0.13 (+0.08%) ▲|GM86.00-0.25 (-0.29%) ▼|GOOG292.52-2.83 (-0.96%) ▼|GOOGL295.77-2.93 (-0.98%) ▼|GS916.56+2.96 (+0.32%) ▲|HD348.69+0.43 (+0.12%) ▲|HON222.46-0.29 (-0.13%) ▼|IBM247.13+2.46 (+1.01%) ▲|INTC59.66-1.54 (-2.52%) ▼|INTU341.70+1.53 (+0.45%) ▲|ISRG443.59+3.70 (+0.84%) ▲|JNJ285.75+2.23 (+0.79%) ▲|JPM346.19+3.37 (+0.98%) ▲|KO99.25+1.81 (+1.86%) ▲|LIN526.06+3.57 (+0.68%) ▲|LLY1,443.50+17.95 (+1.26%) ▲|LMT596.04-8.05 (-1.33%) ▼|LOW227.73+0.27 (+0.12%) ▲|LRCX225.92-7.86 (-3.36%) ▼|MA661.19+8.59 (+1.32%) ▲|MCD271.97-1.66 (-0.61%) ▼|MDLZ67.54+0.98 (+1.47%) ▲|MDT102.86+1.87 (+1.85%) ▲|META641.69+18.08 (+2.90%) ▲|MMM183.66-1.80 (-0.97%) ▼|MO78.64+0.72 (+0.92%) ▲|MRK147.76+0.81 (+0.55%) ▲|MS190.65+1.48 (+0.78%) ▲|MSFT523.88+0.88 (+0.17%) ▲|MU778.31-20.13 (-2.52%) ▼|NEE85.12-0.17 (-0.20%) ▼|NFLX62.15-0.54 (-0.86%) ▼|NKE37.99+0.23 (+0.61%) ▲|NOW102.25+1.59 (+1.58%) ▲|NVDA162.85-3.34 (-2.01%) ▼|ORCL125.35-1.76 (-1.38%) ▼|PEP145.44+3.18 (+2.24%) ▲|PFE28.89+0.06 (+0.21%) ▲|PG169.80+1.77 (+1.05%) ▲|PLTR167.99-3.59 (-2.09%) ▼|PM198.96+2.30 (+1.17%) ▲|QCOM172.47-4.67 (-2.64%) ▼|RTX198.58+0.22 (+0.11%) ▲|SBUX106.44-0.19 (-0.18%) ▼|SCHW92.98+1.58 (+1.73%) ▲|SO93.59+1.12 (+1.21%) ▲|SPG232.97-0.64 (-0.27%) ▼|T22.18+0.00 (+0.00%) ▲|TMO700.22+0.78 (+0.11%) ▲|TMUS169.95-1.08 (-0.63%) ▼|TSLA390.22-7.23 (-1.82%) ▼|TXN303.60-8.88 (-2.84%) ▼|UBER69.69+0.57 (+0.82%) ▲|UNH407.46+2.33 (+0.58%) ▲|UNP302.44-1.76 (-0.58%) ▼|UPS112.40+2.02 (+1.83%) ▲|USB60.99+0.52 (+0.86%) ▲|V425.76+5.45 (+1.30%) ▲|VZ46.36-0.19 (-0.41%) ▼|WFC86.05+0.29 (+0.34%) ▲|WMT128.09+1.90 (+1.51%) ▲|XOM170.59+0.81 (+0.48%) ▲|
7.3 C
New York
Saturday, November 14, 2026

Tag: management

newsFORsourcecompanycontentinformationreleases1IT

Nixol Capsules Launch in the UK: A Natural Path to Weight Management and Metabolic Support

Nixol introduces a new natural supplement in the United Kingdom to support metabolism, curb cravings, and promote healthy weight loss management using vegan-friendly ingredients. 
Nixol introduces a new natural supplement in the United Kingdom to support metabolism, curb cravings, and promote healthy weight loss management using vegan-friendly ingredients.

Kaanch Network Presale Positions Project Among Top Altcoins and Best Crypto Opportunities of 2025

DUBAI, United Arab Emirates, June 21, 2025 (GLOBE NEWSWIRE) -- Kaanch Network’s token is set to be listed on BitMart and LBank exchanges on June 30th, an important milestone in the project’s mission to revolutionize decentralized finance and asset management. Built on a scalable and affordable Layer 1 blockchain with real-world applications, Kaanch offers developers, business owners, and investors a compelling platform for growth in 2025 and beyond.

New Inclave Casinos 2025: Raging Bull Slots Adds Inclave Payment Solution

Raging Bull has introduced Inclave payment solutions to match its broad gaming library, generous bonuses, and secure login. 
Raging Bull has introduced Inclave payment solutions to match its broad gaming library, generous bonuses, and secure login.

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit...

SAN DIEGO, June 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI’s top executives with violations of the Securities Exchange Act of 1934.

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Government of Pakistan Recommends President Donald J. Trump for 2026 Nobel Peace Prize

Pakistan nominates President Trump of the US for the Nobel Peace Prize for diffusing potential nuclear war with neighbor India

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The...

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

IIM Udaipur Concludes Executive Education Training Program for PM SHRI School Principals in Collaboration with RSSP Jaipur

UDAIPUR, India, June 21, 2025 /PRNewswire/ -- Indian Institute of Management Udaipur (IIM Udaipur), in collaboration with the Rajasthan School Shiksha Parishad (RSSP), Jaipur,...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsManagement

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers